EPRX Stock Overview
A clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Eupraxia Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.34 |
| 52 Week High | CA$6.49 |
| 52 Week Low | CA$3.07 |
| Beta | 1.52 |
| 1 Month Change | -2.73% |
| 3 Month Change | -6.32% |
| 1 Year Change | 46.30% |
| 3 Year Change | 258.39% |
| 5 Year Change | n/a |
| Change since IPO | -22.61% |
Recent News & Updates
Shareholder Returns
| EPRX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 1.5% | -4.1% | 0.9% |
| 1Y | 46.3% | -5.1% | 13.3% |
Return vs Industry: EPRX exceeded the Canadian Biotechs industry which returned 1.9% over the past year.
Return vs Market: EPRX exceeded the Canadian Market which returned 15.1% over the past year.
Price Volatility
| EPRX volatility | |
|---|---|
| EPRX Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in CA Market | 18.8% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: EPRX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: EPRX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 33 | James Helliwell | www.eupraxiapharma.com |
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
Eupraxia Pharmaceuticals Inc. Fundamentals Summary
| EPRX fundamental statistics | |
|---|---|
| Market cap | CA$193.77m |
| Earnings (TTM) | -CA$37.43m |
| Revenue (TTM) | n/a |
Is EPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$27.27m |
| Earnings | -US$27.27m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did EPRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/30 13:22 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eupraxia Pharmaceuticals Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Gary Nachman | Raymond James & Associates |